# A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)

> **NCT00959699** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 99 (actual)

## Conditions studied

- HIV Infections
- Hepatitis C
- HCV Infection

## Interventions

- **DRUG:** PegIFN-2b
- **DRUG:** RBV
- **DRUG:** Placebo to Boceprevir
- **DRUG:** Boceprevir

## Key facts

- **NCT ID:** NCT00959699
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2012-05
- **Final completion:** 2012-10
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2017-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00959699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00959699, "A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT00959699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*